drugset / Trial / NCT02605044
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
Timeline
- Start
- 2014-01
- Primary completion
- 2017-12
- Completion
- 2017-12
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision based on portfolio prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |